IMPACT

Welcome to the Brand page for “IMPACT”, which is offered here for Scientific analysis services, neoepitope selection; neoepitope research, development and production of pharmaceuticals comprising personalized adoptive cell therapies; scientific analysis of neoepitopes; research, development and production of pharmaceuticals comprising the selection of and genetic encoding of neoepitopes; research, development and production of pharmaceuticals comprising adoptive cell therapies design of personalized adoptive cell therapies; medical analysis services, detection of truncal cancer mutations in patient tumor cells; developing personal scientific treatment strategies for patients with diagnosed cancer; pharmaceutical product development and evaluation services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials involving neoepitopes; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, cancer immunotherapy platforms for manufacturing therapeutics; scientific collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; conducting early evaluations in the field of new pharmaceuticals; providing scientific research advice regarding selection of a neoepitope for the design of a cell therapy and/or immunotherapy product;.

Its status is currently believed to be active. Its class is unavailable. “IMPACT” is believed to be currently owned by “PACT Pharma, Inc.”